PDS Biotechnology (PDSB) to Announce Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect PDS Biotechnology to post earnings of ($0.13) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

PDS Biotechnology Stock Performance

Shares of NASDAQ:PDSB opened at $0.72 on Wednesday. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.55. The company’s 50 day moving average price is $0.88 and its two-hundred day moving average price is $0.88. The firm has a market cap of $40.26 million, a PE ratio of -1.07 and a beta of 1.62. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73.

Institutional Trading of PDS Biotechnology

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in PDS Biotechnology in the fourth quarter valued at approximately $25,000. Marshall Wace LLP bought a new stake in PDS Biotechnology during the second quarter worth $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the 2nd quarter valued at $92,000. Susquehanna International Group LLP boosted its holdings in shares of PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PDSB shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Wall Street Zen cut PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.